Novocure (Nasdaq:NVCR) announced that the FDA granted approval for its Optune Pax treatment for advanced pancreatic cancer.
13d
U.S. FDA Approves Novocure's Optune Pax(R) for the Treatment of Locally Advanced Pancreatic Cancer
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax (R) for the treatment of adult patients with locally advanced pancreatic cancer concomitant ...
Optune Lua is now approved for use concurrently with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on or after platinum-based chemotherapy Ministry ...
New flexible arrays are lighter, thinner and designed to improve comfort for Optune Gio users ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug ...
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors or docetaxel, for the treatment of adult ...
The Food and Drug Administration approved its Optune Pax product, which delivers tumor treating fields, for certain ...
(RTTNews) - Novocure (NVCR) announced the FDA approved new Head Flexible Electrode transducer arrays for use with Optune Gio for the treatment of adult patients with glioblastoma multiforme. Novocure ...
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of ...
Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet ...
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax ® for the treatment of adult patients with locally advanced pancreatic cancer concomitant ...
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC) Optune Lua is now approved for use concurrently with ...
Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer Phase 3 PANOVA-3 trial showed a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results